{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:18Z","timestamp":1786119198057,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/cad.0b013e32834ea5d0","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T06:14:26Z","timestamp":1323324866000},"page":"321-325","source":"Crossref","is-referenced-by-count":5,"title":["Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer"],"prefix":"10.1097","volume":"23","author":[{"given":"Jong Ha","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heon Jong","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Soo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sokbom","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210227","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-9-20210227","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010.","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"R3-9-20210227","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3802\/jgo.2010.21.4.241","article-title":"Epidemiological characteristics of ovarian cancer in Korea.","volume":"21","author":"Park","year":"2010","journal-title":"J Gynecol Oncol"},{"key":"R4-9-20210227","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"R5-9-20210227","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatinpaclitaxel versus carboplatinpaclitaxel as first-line treatment of ovarian cancer.","volume":"95","author":"Du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R6-9-20210227","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.","volume":"22","author":"Markman","year":"2004","journal-title":"J Clin Oncol"},{"key":"R7-9-20210227","first-page":"1425","article-title":"Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.","volume":"57","author":"Whitacre","year":"1997","journal-title":"Cancer Res"},{"key":"R8-9-20210227","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2005.12.003","article-title":"Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.","volume":"102","author":"Rose","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R10-9-20210227","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/BF02975379","article-title":"Antitumor activity of 7-2-(N-isopropylamino)ethyl-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.","volume":"21","author":"Lee","year":"1998","journal-title":"Arch Pharm Res"},{"key":"R11-9-20210227","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/cncr.24719","article-title":"Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.","volume":"116","author":"Lee","year":"2010","journal-title":"Cancer"},{"key":"R12-9-20210227","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/cncr.25710","article-title":"Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.","volume":"117","author":"Choi","year":"2011","journal-title":"Cancer"},{"key":"R13-9-20210227","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdm437","article-title":"Belotecan, a new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"key":"R14-9-20210227","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ygyno.2007.11.023","article-title":"Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.","volume":"109","author":"Lee","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R15-9-20210227","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/COC.0b013e3181a650bc","article-title":"Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.","volume":"33","author":"Nam","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"R16-9-20210227","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1749-6632.2009.04885.x","article-title":"Phase IIIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.","volume":"1171","author":"Kim","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"R17-9-20210227","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/cncr.20921","article-title":"Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase III study.","volume":"103","author":"Gronlund","year":"2005","journal-title":"Cancer"},{"key":"R18-9-20210227","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.bjc.6602657","article-title":"Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.","volume":"93","author":"Levitt","year":"2005","journal-title":"Br J Cancer"},{"key":"R19-9-20210227","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.","volume":"26","author":"Sehouli","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32834ea5d0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:58:14Z","timestamp":1786039094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201203000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32834ea5d0","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}